The Effects of Simultaneous Administration of Dietary Conjugated Linoleic Acid and Telmisartan on Cardiovascular Risks in Rats |
| |
Authors: | Mohammad M. Abdullah,Zuyuan Xu,Grant N. Pierce,Mohammed H. Moghadasian |
| |
Affiliation: | (1) Department of Human Nutritional Sciences, The University of Manitoba and St. Boniface General Hospital Research Centre, Winnipeg, MB, Canada;(2) Department of Pathology, The University of Manitoba and St. Boniface General Hospital Research Centre, Winnipeg, MB, Canada;(3) The Canadian Centre for Agri-Food Research in Health and Medicine (CCARM), The University of Manitoba and St. Boniface General Hospital Research Centre, Winnipeg, MB, Canada;(4) Pathology Research Laboratory, St. Boniface General Hospital Research Centre, 351 Tache Ave, Winnipeg, MB, Canada, R2H 2A6 |
| |
Abstract: | Dietary conjugated linoleic acid (CLA) and the antihypertensive drug, telmisartan, have both been shown to modify cardiovascular risks. The effects of a combination of these two agents have, however, not been investigated. This 20 week study sought to assess the therapeutic potential of a CLA/telmisartan co-administration in rats fed a high-fructose high-fat diet. Thirty-three male Sprague–Dawley rats were randomly assigned to five experimental groups, including control, losartan, telmisartan, CLA, and CLA + telmisartan-treated animals. Body weight, blood pressure, and blood levels of lipids, glucose, insulin, and inflammatory markers were measured. Co-administration of CLA and telmisartan resulted in significant (P < 0.05) reductions in body weight, visceral fat, serum total cholesterol, triglycerides, glucose, plasma insulin concentrations, and systolic blood pressure compared with those in the control group. Moreover, plasma levels of IL1-α and IFN-γ were reduced and levels of IL1-β, IL-4, IL-6, and IL-10, plus TNF-α were increased in the co-therapy group, compared with controls. In conclusion, this study suggests that a combination of CLA with telmisartan may modify several risk factors of cardiovascular disease commonly seen in metabolic syndrome. This combination of nutraceuticals and pharmaceuticals may be a safe and cost-effective strategy in a number of high-risk subjects. Future studies will further document clinical benefits of such combination therapy. |
| |
Keywords: | Cardiovascular disease Metabolic syndrome Obesity Diabetes Conjugated linoleic acid Telmisartan Peroxisome proliferator-activated receptor Fatty acid Angiotensin II receptor blocker |
本文献已被 PubMed SpringerLink 等数据库收录! |
|